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Prior Events Predict Cerebrovascular and Coronary
Outcomes in the PROGRESS Trial
Hisatomi Arima, MD; Christophe Tzourio, MD; Ken Butcher, MD; Craig Anderson, MD;
Marie-Germaine Bousser, MD; Kennedy R. Lees, MD; John L. Reid, DM; Teruo Omae, MD;
Mark Woodward, PhD; Stephen MacMahon, PhD; John Chalmers, MD; for the
PROGRESS Collaborative Group
Background and Purpose—The relationship between baseline and recurrent vascular events may be important in the
targeting of secondary prevention strategies. We examined the relationship between initial event and various types of
further vascular outcomes and associated effects of blood pressure (BP)–lowering.
Methods—Subsidiary analyses of the Perindopril Protection Against Recurrent Stroke Study (PROGRESS) trial, a
randomized, placebo-controlled trial that established the benefits of BP–lowering in 6105 patients (mean age 64 years,
30% female) with cerebrovascular disease, randomly assigned to either active treatment (perindopril for all, plus
indapamide in those with neither an indication for, nor a contraindication to, a diuretic) or placebo(s).
Results—Stroke subtypes and coronary events were associated with 1.5- to 6.6-fold greater risk of recurrence of the same
event (hazard ratios, 1.51 to 6.64; P0.1 for large artery infarction, P0.0001 for other events). However, 46% to 92%
of further vascular outcomes were not of the same type. Active treatment produced comparable reductions in the risk
of vascular outcomes among patients with a broad range of vascular events at entry (relative risk reduction, 25%;
P0.0001 for ischemic stroke; 42%, P0.0006 for hemorrhagic stroke; 17%, P0.3 for coronary events;
P homogeneity0.4).
Conclusions—Patients with previous vascular events are at high risk of recurrences of the same event. However, because
they are also at risk of other vascular outcomes, a broad range of secondary prevention strategies is necessary for their
treatment. BP–lowering is likely to be one of the most effective and generalizable strategies across a variety of major
vascular events including stroke and myocardial infarction. (Stroke. 2006;37:1497-1502.)
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Despite many effective strategies for the secondary pre-vention of major vascular events,1 patients remain at
high risk of both recurrence of the baseline event2–4 and of
other manifestations of vascular disease.2,3,5–8 These findings
are consistent with progression of a common underlying
mechanism, such as atherosclerosis, affecting a number of
target organs including the heart, the brain, and the kidneys.
They could also reflect the multifactorial effects of a hetero-
geneous group of risk factors such as suboptimal control of
blood pressure (BP), cholesterol, or diabetes. A better under-
standing of the pattern of recurrence of further vascular
events may be helpful for better targeting of existing treat-
ments and in devising effective new strategies for secondary
prevention in these high-risk patients.
The Perindopril Protection Against Recurrent Stroke Study
(PROGRESS) trial was a randomized, placebo-controlled
trial that established the effects of BP–lowering in patients
with cerebrovascular disease.9 Previous reports of the asso-
ciation between the types of index cerebrovascular event and
recurrent strokes in the PROGRESS trial were limited to the
2 broad categories of ischemic and hemorrhagic stroke.10 In
this article, we provide additional information about the
relationship between ischemic stroke subtypes and coronary
heart disease (CHD) occurring before randomization and
during follow-up in the PROGRESS trial. We also studied the
effects of BP–lowering treatment on the association between
particular prior events and various types of vascular events
during follow-up.
Materials and Methods
Study Design and Participants
The design of PROGRESS has been described in detail elsewhere.9
Briefly, 6105 participants were recruited between May 1995 and
November 1997. Participants were eligible if they had a history of a
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cerebrovascular event (stroke or transient ischemic attack [TIA], but
not subarachnoid hemorrhage) within the previous 5 years. In
addition, participants were required to have no clear indication for, or
contraindication to, treatment with an angiotensin-converting–en-
zyme inhibitor. There were no formal BP thresholds for entry. The
institutional ethics committee of each collaborating center approved the
trial, all participants provided written informed consent, and procedures
followed were in accordance with institutional guidelines.
Randomized Treatment
Participants who tolerated at least 4 weeks of run-in therapy with
perindopril were randomly assigned, in a double-blind manner, to
continued active treatment or placebo. Active treatment comprised a
flexible regimen based on perindopril (4 mg daily), with the addition
of indapamide (2.5 mg daily; or 2 mg daily in Japan) in those
participants for whom the responsible study physician felt that there
was no specific indication for, nor contraindication to, the use of a
diuretic. Those participants assigned placebo received tablets iden-
tical in appearance to the active agent(s).
Definition of Baseline Vascular Events
Baseline cerebrovascular events were defined as the most recent
stroke or TIA by local study investigators using evidence from the
medical history and physical examination supplemented by clinical
records or radiological findings if available. The nature of the index
cerebrovascular event was confirmed with neuroimaging in 90% of
total participants and in 94% of participants with ischemic stroke.9,10
Diagnoses of stroke and TIA were defined according to standard
criteria11 (codes 431, 433, 434, 436, and 437 in the 9th revision of the
International Classification of Diseases [ICD9]). Baseline strokes
were subclassified as ischemic (ICD9 codes 433 to 434), hemor-
rhagic (431) or unknown type (436–437). According to definitions
provided in the study protocol, baseline ischemic strokes were
further subclassified into the following: (i) lacunar infarction (symp-
toms of a lacunar syndrome, normal consciousness and cortical
functions, and normal computerized tomographic findings or a small,
relevant subcortical/brain stem infarct), (ii) cardioembolic infarction
(no lacunar characteristics, no definite evidence of large artery
disease, and a cardioembolic source [nonvalvular atrial fibrillation
64%, valvular heart disease 17%, and other cardioembolic sources
19%]), (iii) large artery infarction (no lacunar characteristics, no
cardioembolic source, and evidence of large artery disease), or (iv)
unknown ischemic stroke. For subjects experiencing 1 cerebrovas-
cular event, only the most recent event was used in the analysis.
The presence of major CHD at baseline was defined by local study
investigators using evidence from the medical history and physical
examination supplemented by clinical records, electrocardiographic,
echocardiographic, and angiographic findings if available. Major
CHD was defined as prior myocardial infarction diagnosed with the
combination of an appropriate clinical history supported by electro-
cardiographic changes and an elevation of cardiac enzymes.9
Outcomes
The outcomes of the present investigation were total major vascular
events (nonfatal stroke, nonfatal myocardial infarction, or death
attributable to any vascular cause), stroke, and major CHD. Classi-
fication of outcome stroke subtypes during follow-up was based on
radiographic evidence or autopsy reports in 89% of patients.9,10
Strokes were subclassified into ischemic and hemorrhagic type
according to the ICD9 codes in the same way as baseline strokes.
However, whereas the further classification for baseline ischemic stroke
was according to definitions provided in the protocol, the Trial of Org
10172 in Acute Stroke Treatment (TOAST) criteria12 were used to
further subclassify ischemic stroke recorded during follow-up as one of
lacunar infarction, cardioembolic infarction, large artery infarction, or
ischemic stroke of unknown type. Major CHD during follow-up was
defined as nonfatal myocardial infarction or death attributable to
CHD. All these events were reviewed and validated by an end point
adjudication committee that was blinded to study treatment.9 It
should be noted that although the end point adjudication committee
had no information regarding initial events, it is possible that
imaging reports of outcome events might have provided some
information regarding initial events. Only the first event relevant to
each outcome was included in each analysis.
Statistical Analysis
The associations between the vascular event before randomization
and major vascular outcomes during follow-up were investigated
using Cox proportional hazards models including the covariates age,
gender, current smoking, diabetes, systolic BP, randomized study
treatment, and planned use of combination therapy. The relative
effects of randomized treatment on major vascular events were
calculated using univariate Cox proportional hazards models, and the
absolute effects were calculated as percentage difference in the rates
of events over 5 years according to the principle of intention-to-treat.
BP differences between randomized groups were estimated from
linear mixed models. Because the overall effects of treatment on BP
and events were greater among participants treated with combination
therapy than among those treated with single-drug therapy,9 treat-
ment effects on BP and events in subgroups were standardized for
the proportions of the study population for whom combination (58%)
or single-drug therapy (42%) was prescribed, by taking weighted
averages of the estimates obtained for the 2 therapies.9 Percentage
risk reductions were calculated as (1hazard ratio)100 and re-
ported with 95% CI.
Results
Baseline Characteristics
The characteristics of randomized participants have been
reported previously9,10 and are summarized in Table 1. Mean
age was 64 years (men 64 years, women 65 years). Mean age
varied in the different cerebrovascular and CHD subgroups,
but similar patterns were observed for both men and women
(Table 1). There were no significant differences in these
baseline characteristics between randomized groups for any
of the patient groups with different cerebrovascular and CHD
histories.
Association Between Initial and Outcome
Vascular Events
During a mean follow-up of 3.9 years, a total of 1062 major
vascular events occurred (4.8% per annum). The risk of major
vascular outcomes was 41% (95% CI, 18% to 70%; P0.0002)
greater among patients with an index event of stroke than among
those with TIA, after adjusting for other cardiovascular risk
factors and randomized treatment. In patients with prior stroke,
recurrent strokes accounted for 637 of 934 recurrent vascular
events (68%; 95% CI, 63% to 73%). Recurrence of the same
stroke subtype as the original index stroke varied between
13% (large artery infarction) and 81% (all ischemic stroke),
as shown in Table 2 and Figure 1. A history of ischemic
stroke was associated with a 59% (95% CI, 30% to 94%;
P0.0001) greater relative risk of further ischemic stroke
compared with patients without previous ischemic stroke,
after adjusting for other cardiovascular risk factors and
randomized treatment (Figure 2). Similarly, significant asso-
ciations between index stroke and recurrence of the same
subtype were observed for lacunar, cardioembolic, and hem-
orrhagic subtypes, an effect known as “tracking” (Figure 2).10
The risk of major vascular events was 69% (95% CI, 40%
to 104%; P0.0001) greater among patients with cerebro-
vascular disease and comorbid CHD at baseline than among
those with cerebrovascular disease alone. Among patients
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with cerebrovascular disease and comorbid CHD, recurrent
CHD accounted for 63 of 127 recurrent vascular events (50%;
Table 2 and Figure 1), and a history of major CHD was
associated with a 3.4-fold greater relative risk of further
coronary outcomes compared with patients without previous
heart disease after adjusting for other cardiovascular risk
factors and randomized treatment (hazard ratio, 3.44; 95% CI,
2.58 to 4.59; P0.0001; Figure 2). Further adjustment for
body mass index, alcohol intake and concomitant therapies
(antiplatelet therapy, oral anticoagulants, and lipid-lowering
therapy) did not alter the findings for stroke and major CHD.
Sensitivity analyses indicated that there were no important
differences in the strength of associations between subgroups
of age, sex, geographic region, and history of hypertension.
Treatment Effects on BP and the Risk of
Recurrent Vascular Events
During follow-up, the mean difference in BP between partic-
ipants assigned active treatment and those assigned placebo
was 9.1/4.0 mm Hg in patients with a prior ischemic stroke,
10.8/4.4 mm Hg in those with prior hemorrhagic stroke, and
9.1/3.4 mm Hg in those with major CHD at entry (P homo-
TABLE 1. Baseline Characteristics Among Patients With Different Cerebrovascular and CHD Histories
Cerebrovascular Disease History* CHD History
Ischemic
(n4262)
Hemorrhagic
(n611)
Unknown
(n251) TIA (n981)
Major CHD
(n427) No Major CHD (n5678)
Demographic
Mean age, y (SD) 64 (9) 61 (10) 68 (10) 64 (10) 68 (8) 64 (10)
Women, % 29 29 36 34 16 31
Asian,† % 42 58 10 19 17 40
Body mass index (kg/m2) 25.6 (3.8) 25.1 (3.7) 26.1 (4.2) 26.0 (3.8) 26.4 (3.8) 25.6 (3.8)
Major vascular event history, %
Qualifying event
Ischemic stroke 100 5 6 0 71 71
Hemorrhagic stroke 1 100 1 0 4 11
Unknown stroke 1 0 100 0 7 4
TIA 8 4 16 100 30 22
Median time since qualifying event, months
(interquartile interval)
9 (4–23) 12 (5–25) 9 (4–23) 7 (4–17) 9 (4–22) 9 (4–22)
Major CHD 7 2 12 9 100 0
Other medical history, %
Current smoker 21 16 19 19 17 20
Current alcohol use‡ 39 29 51 50 49 40
Diabetes
Non–insulin-dependent diabetes 12 9 8 8 12 11
Insulin-dependent diabetes 2 1 2 1 3 1
Carotid disease‡ 7 1 10 11 13 6
Atrial fibrillation 8 4 9 8 11 8
BP
Mean SBP, mm Hg (SD) 147 (19) 145 (18) 150 (22) 147 (20) 147 (20) 147 (19)
Mean DBP, mm Hg (SD) 86 (11) 87 (11) 84 (11) 85 (11) 84 (11) 86 (11)
Hypertension,§ % 48 50 44 46 43 48
Medication, %
Antihypertensive therapy¶ 50 68 45 43 51 50
Antiplatelet therapy 77 18 85 82 81 72
Oral anticoagulants 10 1 9 10 16 9
Lipid-lowering therapy 15 8 9 16 25 13
Study treatment, %
Active treatment 50 50 47 50 50 50
Combination therapy 59 59 50 57 60 58
SBP indicates systolic blood pressure; DBP, diastolic blood pressure.
*The most recent stroke or TIA; †participants recruited from People’s Republic of China or Japan; ‡consumers at least 1 alcoholic drink per week, §previous carotid
endarterectomy, previous carotid angioplasty or carotid stenosis 50% (confirmed by angiogram or Doppler); ¶SBP160 mm Hg or DBP90 mm Hg; currently
treated hypertension.
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geneity0.1 for systolic BP difference, 0.4 for diastolic BP
difference).
Active treatment significantly reduced the relative risk of
major vascular events during follow-up in subgroups with
prior ischemic (relative risk reduction 25%; 95% CI, 13% to
35%; P0.0001) and hemorrhagic stroke (42%; 95% CI,
14% to 60%; P0.0006; Figure 3). However, in participants
with major CHD at entry numbering only 427, there was a
17% (95% CI, 18% to 42%; P0.3) nonsignificant trend
toward a reduction, possibly reflecting the small number of
subjects (Figure 3). There were no differences in the size of the
relative treatment effect in patients with prior ischemic stoke,
hemorrhagic stroke, or major CHD (P homogeneity0.4).
There were also comparable benefits obtained from active
treatment on relative risks of both recurrence of the initial
vascular event and the incidence of other vascular outcomes
in the subgroups with prior ischemic stroke, hemorrhagic
stroke, or major CHD (P homogeneity 0.1). These results
were similar for men and women in each subgroup. Adjust-
ment for various baseline characteristics (age, gender, body
mass index, current smoking, diabetes, alcohol intake, sys-
tolic BP), study treatment, and concomitant therapy (anti-
platelet therapy, oral anticoagulants, and lipid-lowering ther-
apy) did not alter the findings.
The absolute treatment effects on major vascular events
amounted to 4.7% (95% CI, 2.2% to 7.2%; P0.0003), 7.9%
(95% CI, 1.1% to 14.6%; P0.02), and 5.3% (95% CI,
5.0% to 15.6%; P0.3) over 5 years among patients with
prior ischemic stroke, hemorrhagic stroke, and major CHD,
respectively (P homogeneity0.7; Figure 3). A significant
TABLE 2. Risks of Cause-Specific Major Vascular Events Among Patients With Different Cerebrovascular and CHD Histories
Outcome
Event
Cerebrovascular Disease History* CHD History
All IS
(n4262)
LI
(n2031)
CEI
(n236)
LAI
(n950)
UI
(n1045)
HS
(n611)
US
(n251)
TIA
(n981)
Major CHD
(n427)
No Major CHD
(n5678)
Major vascular
event
764 (4.9%) 354 (4.8%) 45 (5.3%) 177 (5.1%) 188 (5.0%) 110 (4.9%) 60 (7.0%) 128 (3.6%) 127 (9.0%) 935 (4.5%)
All stroke 518 (3.3%) 243 (3.3%) 31 (3.6%) 124 (3.5%) 120 (3.2%) 86 (3.8%) 33 (3.8%) 71 (2.0%) 59 (4.1%) 649 (3.1%)
All IS 422 (2.7%) 195 (2.6%) 27 (3.1%) 98 (2.8%) 102 (2.7%) 30 (1.3%) 23 (2.6%) 57 (1.6%) 52 (3.6%) 480 (2.3%)
LI 112 (0.7%) 72 (0.9%) 5 (0.6%) 20 (0.5%) 15 (0.4%) 10 (0.4%) 2 (0.2%) 12 (0.3%) 10 (0.6%) 126 (0.6%)
CEI 29 (0.2%) 9 (0.1%) 10 (1.1%) 2 (0.1%) 8 (0.2%) 0 (0.0%) 1 (0.1%) 3 (0.1%) 4 (0.3%) 29 (0.1%)
LAI 50 (0.3%) 17 (0.2%) 3 (0.3%) 16 (0.4%) 14 (0.4%) 2 (0.1%) 8 (0.9%) 10 (0.3%) 9 (0.6%) 61 (0.3%)
UI 231 (1.4%) 97 (1.3%) 9 (1.0%) 60 (1.7%) 65 (1.7%) 18 (0.8%) 12 (1.3%) 32 (0.9%) 29 (1.9%) 264 (1.2%)
HS 46 (0.3%) 28 (0.4%) 2 (0.2%) 9 (0.2%) 7 (0.2%) 45 (1.9%) 2 (0.2%) 6 (0.2%) 3 (0.2%) 96 (0.4%)
US 61 (0.4%) 27 (0.4%) 2 (0.2%) 19 (0.5%) 13 (0.3%) 14 (0.6%) 10 (1.1%) 8 (0.2%) 7 (0.4%) 86 (0.4%)
Major CHD 188 (1.2%) 81 (1.1%) 8 (0.9%) 45 (1.3%) 54 (1.4%) 17 (0.8%) 22 (2.6%) 42 (1.2%) 63 (4.5%) 206 (1.0%)
Values are No. of events (annual rates).
IS indicates ischemic stroke; LI, lacunar infarction; CEI, cardioembolic infarction; LAI, large artery infarction; UI, unknown ischemic stroke; HS, hemorrhagic stroke;
US, unknown stroke.
*Cerebrovascular disease history indicates the most recent stroke or TIA.
Figure 1. Incidence of cause-specific
major vascular events among patients
with different cerebrovascular and CHD
histories. IS indicates ischemic stroke; LI,
lacunar infarction; CEI, cardioembolic
infarction; LAI, large artery infarction; UI,
unknown ischemic stroke; HS, hemor-
rhagic stroke; US, unknown stroke;
*P0.05 versus TIA; †P0.05 versus no
major CHD.
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portion of the absolute benefits of therapy was attributable to
reduction in the risks of recurrence of the initial event. In
patients with a baseline ischemic stroke, hemorrhagic stroke,
and major CHD, this amounted to 48%, 70%, and 78%,
respectively, of the total absolute risk reduction in vascular
events (Figure 3).
Discussion
The present analysis from the PROGRESS trial demonstrated
that the most common type of recurrent vascular event was
one that was identical to the patient’s initial manifestation of
vascular disease, an effect known as “tracking”.10 This
finding supports earlier reports suggesting tracking effects2,3
of vascular events. Previous observational studies have also
demonstrated that recurrent strokes are often of the same type
as the initial event in many patients.13–17 Similarly, patients
with a history of CHD are at higher risk of recurrence of
cardiac events than of other vascular outcomes.2 These results
provide strong evidence for the tracking of stroke subtypes
and of associated CHD.
The present analysis from the PROGRESS trial also
demonstrated that patients with a history of vascular disease
were at high risk of other vascular events, though somewhat
less than for the same event. These findings are consistent
with previous reports2,3,5–8,13–17 that while patients with a
history of cerebrovascular disease experience stroke risks of
4% to 6% annually, they experience other vascular events, at
a lower level of 1% to 3% per year.2,3 This may reflect
progression of a common underlying pathophysiological
mechanism, such as atherosclerosis affecting a number of
target organs. In order to provide the maximum benefits of
vascular prevention, it is, therefore, important to concentrate
not only on treatment of the cause of the original event but
also on the management of a heterogeneous group of vascular
risk factors.
This large-scale randomized trial also demonstrated that
perindopril-based BP–lowering treatment produced compara-
ble reductions in the risk of major vascular outcomes among
a heterogeneous group of patients with different vascular
events at entry. A large part of absolute risk reduction was
obtained from reductions of the same subtype as prior
episode, but this reflects the higher absolute risks of the tracked
events. Benefits obtained from active treatment were compa-
rable for both recurrence of the initial event and the incidence
of other vascular outcomes. This suggests that the beneficial
effects of BP–lowering treatment are generalizable across a
variety of major vascular events with different underlying
etiologies.
This study has a number of strengths and limitations.
Although this is the largest patient sample used to address the
Figure 2. Hazard ratio of initial event re-
currence among patients with different
cerebrovascular and CHD histories. Solid
boxes represent estimates of hazard ratio
on ischemic stroke, hemorrhagic stroke,
and major CHD; unfilled boxes, estimates
of hazard ratio on ischemic stroke sub-
types. Centers of the boxes are placed
at the estimates of hazard ratio; areas of the
boxes are proportional to the number of
events. Horizontal lines represent 95% CI.
Figure 3. Relative and absolute effects of randomized treatment on the risk of major vascular events among patients with prior ische-
mic stroke, hemorrhagic stroke, and major CHD. Left panel: Solid boxes represent estimates of effect in subgroups; diamonds, esti-
mate and 95% CI for overall effect. The vertical broken line represents point estimate for overall effect. Other conventions as for Figure
2. Right panel: Solid, slashed, and blank columns represent the absolute risk reductions for tracked event, other stroke (for ischemic
stroke and hemorrhagic stroke), and other major vascular event, respectively.
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question of tracking to date, the strength of the evidence
about the tracking of event types and about the effects of
BP–lowering on cause-specific vascular outcomes is limited
by the small number of certain events. Another limitation is
that the participants in PROGRESS were limited to patients
who survived an initial stroke or TIA, and the present
findings may not be generalizable to early recurrence or to
severe stroke leading to early death. Several factors may have
potentially reduced the statistical power to detect the influ-
ence of initial stroke subtype on recurrent events. The first is
that the definition used for subclassification of baseline
ischemic stroke, as described in the Materials and Methods
section, was similar but not identical to that of follow-up
stroke (TOAST criteria12); the second is that the control
group used for estimation of the effects of vascular events
before randomization was a cerebrovascular disease population
which is at higher risk of vascular outcomes than a general
population; and the third is that a relatively large number of
follow-up ischemic strokes was adjudicated to constitute an
“unknown” ischemic stroke, attributable to overlapping mecha-
nisms or insufficient supporting investigations.
Summary
Patients with a history of major vascular events are at high
risk both of recurrences of the same type and of other vascular
outcomes. A broad range of secondary prevention strategies
will be necessary for these high-risk patients. BP–lowering
therapy is likely to be the most effective and generalizable of
such strategies that can be applied to patients with a history of
various vascular events such as stroke and myocardial infarc-
tion. Routine BP–lowering should be considered for all patients
presenting with a history of any major vascular event.
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